Phibro Animal Health Corporation reported financial results for the fourth quarter and fiscal year ending June 30, 2025.
The company achieved significant growth in net sales and adjusted EBITDA compared to the previous year.
Phibro's Animal Health portfolio showed strength and balance, contributing to the positive results.
Growth in Net Sales
Net sales increased by $105.5 million in the fourth quarter, reaching $378.7 million, showing a 39% growth compared to the previous year.
Increased Earnings
Net income rose to $17.2 million, a significant increase of $16.5 million compared to the same period last year.
Guidance for 2026
Phibro provided guidance for the fiscal year 2026, with expected net sales of $1.43 billion to $1.48 billion and adjusted EBITDA ranging from $225 million to $235 million.
Portfolio Strength
The company's growth was driven by sustained demand across MFAs, nutritional specialties, and vaccines, with overall adjusted net income increasing by 76%.
Efficiency and Growth
Phibro's successful execution of Phibro Forward initiatives led to unlocking efficiencies and driving sustainable growth, resulting in a 27% growth in annual net sales.
- Phibro's strong financial results reflect the balance and growth of its Animal Health portfolio.
- The company's focus on driving sustainable growth and creating long-term value for stakeholders is evident in the positive performance indicators.
Phibro Animal Health Corporation's exceptional results for the fourth quarter and fiscal year demonstrate its successful execution of growth initiatives, positioning the company for continued success in fiscal year 2026.